Microbial Pharmaceuticals’ goal is to develop the largest, functional library of natural products (through the most robust discovery platform) in order to facilitate a new pipeline of chemical matter into early stage pharmaceutical testing. We have comprised a team of scientists that are well established in the various fields of natural products. Our team offers the necessary expertise and knowledge to bring the metabologenomics platform into thousands of strains of bacteria.
How We Plan To Accomplish This
We plan on creating a pipeline (on an unprecedented scale) to feed compounds from the natural world into pharmaceutical research. Our innovative software, NPkinect, will allow users to sort through natural products of their interest and find related compounds in the same molecular family.
- Firstly, Microbial Pharmaceuticals plans to run our platform on a pilot phase of 50-200 strains as a proof of concept that our platform is functional.
- Next, we will incorporate this data into our NPkinect software in order to “fine tune” the platform.
- We will then move to apply metabologenomics across more strains and continually incorporate this data into our ever-growing NPkinect software.
- Lastly, we will develop partnerships with major pharmaceuticals and provide them access to our highly curated natural product library in order to accelerate the “drugs from bugs” pipeline.
How We Cultivate Our Natural Products
We grow single strains of bacteria and characterize its natural products using state-of-the-art analytical instrumentation. This data is then combined with the metabolomic information from hundreds of strains and implemented into our metabologenomics dataset and eventually NPkinect.
Who Does This Benefit?
Natural products have been honed for thousands of years to interact with real biological systems which makes them very valuable lead compounds for drug development, but their discovery has been a bottleneck in the past. Microbial Pharmaceuticals will alleviate this bottleneck resulting in partnerships with major pharmaceutical companies to deliver much-needed drugs to the world.
Why Investers Should Back Microbial Pharmaceuticals
Microbial Pharmaceuticals offers investors an opportunity to establish a partnership in developing an unprecedented platform for harnessing the future pharmaceutical drugs from the natural world.
These natural products could be used as lead compounds for the development of pharmaceuticals, or used for gaining a better understanding of how diseases (such as cancer) can be targeted for treatment. These compounds and understandings will provide a major improvement to human health outcomes.
Glossary Of Terms
Actinobacteria is a phylum of Gram-positive bacteria with high guanine and cytosine content in their DNA. Although understood primarily as soil bacteria, they might be more abundant in freshwaters. Considered to be one of the most prolific producers of natural products.
A biological system is a complex network of biologically relevant entities. As biological organization spans several scales, examples of biological systems are populations of organisms, or on the organ- and tissue scale in mammals and other animals, the circulatory system, the respiratory system, the nervous system, etc.
On the micro- to the nanoscopic scale, examples of biological systems are cells, organelles, macromolecular complexes and regulatory pathways.